Abstract
In research for a new immunomodulator, we discoverd a novel hydroxypiperidine derivative 9h which was a potent inhibitor of IL-15induced T cell activation. Further modification of 9h gave a potent and orally active agent 10 which was effective in a mouse CIA model.
Keywords: Phenylpyrazoleanilide, IL-15, Prodrug, CIA
Letters in Drug Design & Discovery
Title: Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators
Volume: 5 Issue: 2
Author(s): Hiroyuki Ushio, Seigo Ishibuchi, Kunitomo Adachi, Kouichi Oshita and Kenji Chiba
Affiliation:
Keywords: Phenylpyrazoleanilide, IL-15, Prodrug, CIA
Abstract: In research for a new immunomodulator, we discoverd a novel hydroxypiperidine derivative 9h which was a potent inhibitor of IL-15induced T cell activation. Further modification of 9h gave a potent and orally active agent 10 which was effective in a mouse CIA model.
Export Options
About this article
Cite this article as:
Ushio Hiroyuki, Ishibuchi Seigo, Adachi Kunitomo, Oshita Kouichi and Chiba Kenji, Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators, Letters in Drug Design & Discovery 2008; 5 (2) . https://dx.doi.org/10.2174/157018008783928427
DOI https://dx.doi.org/10.2174/157018008783928427 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Editorial
Current Medicinal Chemistry A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy
Current Cancer Drug Targets Multi-target Pharmacological Effects of Platycodin D
Mini-Reviews in Organic Chemistry Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders Mechanisms and Consequences of Protein Aggregation: The Role of Folding Intermediates
Current Protein & Peptide Science Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Epitope Discovery and Their Use in Peptide Based Vaccines
Current Pharmaceutical Design Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease
Current Neuropharmacology Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Characterization of Phosphorylated Proteins Using Mass Spectrometry
Current Protein & Peptide Science Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity
Current Medicinal Chemistry